Perrigo Company plc (PRGO) is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being. The company boasts unparalleled quality, value, and service to consumers globally. Perrigo, a name synonymous with Affordable Self-Care Products, thrives on a foundation of delivering high-value solutions for a wide array of unmet consumer health demands.
Perrigo was founded in 1887 and is presently headquartered in Dublin, Ireland. After more than 130 years of continuous operation, it is now a major global player in the Consumer Self-Care industry. The company's extensive portfolio contains many of the world's most recognized and trusted OTC brands, including cough and cold remedies, analgesics, gastrointestinal and dermatological treatments, as well as infant nutrition products.
The company’s global footprint spans around 30 countries, and it supplies to more than 100 markets worldwide, making it indeed a global powerhouse in the consumer health industry. As a testament to its commitment to quality, Perrigo operates according to the highest standards of quality and compliance, with numerous manufacturing facilities globally, which are FDA (US Food and Drug Administration), EMA (European Medicines Agency), and other globally approved.
Perrigo embodies a strong business strategy which emphasizes sustained investment in product innovations, strategic acquisitions and partnerships, and adhering to strong governance and environmental, social, and corporate stewardship. Its focus is on developing, manufacturing, and delivering Affordable Self-Care Products that consumers trust, while providing exceptional shareholder value.
Worth mentioning is Perrigo’s active stance on corporate responsibility. The company is committed to doing right by its clients, employees, and the communities in which they reside and operate. It is dedicated to ethical business behavior, human rights, worker safety, and environmental sustainability. Through such actions, Perrigo hopes to make a meaningful impact on the overall health and wellness of society while promoting a more sustainable planet.
In recent years, Perrigo has been rapidly shifting its focus from prescription pharmaceuticals to OTC products and dietary supplements, leading its transformation into a consumer-focused self-care company. As the company moves forward, its aim is to become the first choice for consumers and customers looking for health and wellness solutions. Led by a dynamic and visionary management team, Perrigo is well-poised for continued growth as it leverages its rich history and anticipates future opportunities in the evolving self-care landscape.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Squarepoint Ops LLC significantly reduced its stake in Perrigo Company plc (NYSE:PRGO) by 95.5% in the second quarter, selling 443,842 shares and retaining only 20,900 shares. Despite this, institutional investors collectively own 95.91% of PRGO. Perrigo reported strong quarterly earnings, beating consensus estimates with an EPS of $0.50 and revenue of $1.02 billion, and maintains a quarterly dividend of $0.29.
Perrigo Company plc (NYSE:PRGO) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $19.33. The company's shares recently traded down 1.5% to $13.28, despite exceeding quarterly EPS estimates with $0.50 against a $0.39 consensus. Institutional investors and hedge funds own a significant 95.9% of the stock.
Perrigo Company plc Director Geoffrey M. Parker completed transactions involving the vesting of Restricted Stock Units (RSUs) and subsequent share withholding for tax obligations. On September 11, 2026, 1,263 RSUs were converted into ordinary shares, and 607 shares were sold to cover taxes, resulting in Parker directly owning 33,873 ordinary shares. He also holds indirect ownership through a Revocable Trust and a Roth IRA.
This article analyzes Perrigo Company Plc (PRGO) and its impact on rotational strategy timing, highlighting strong near- and mid-term sentiment but a weak long-term outlook. It presents AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for PRGO. The analysis notes compelling upside potential due to the absence of resistance levels above the current price.
Perrigo Company plc (NYSE:PRGO) has received a consensus "Hold" rating from six brokerages, with an average 12-month price target of $19.33, significantly above its current share price of $14.19. The company recently reported strong quarterly EPS of $0.50, exceeding estimates, and declared a quarterly dividend of $0.29, yielding an annualized 8.2%. Institutional investors hold a substantial 95.91% of Perrigo's shares, with notable increases in positions by some funds.
Perrigo Co. PLC (PRGO) saw its stock advance by 7.63% to $13.96, outperforming the broader market on a strong trading day. Both the S&P 500 Index and the Dow Jones Industrial Average also registered gains. This marks the second consecutive day of gains for Perrigo Co. PLC stock.